Scarica l'app Stockscreener
21.34
1.70%
-0.37
Dopo l'orario di chiusura:
21.33
-0.01
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.71
Aprire:
$21.94
Volume 24 ore:
2.54M
Relative Volume:
0.94
Capitalizzazione di mercato:
$2.06B
Reddito:
$672.72M
Utile/perdita netta:
$-575.44M
Rapporto P/E:
-3.6566
EPS:
-5.8361
Flusso di cassa netto:
$-487.00M
1 W Prestazione:
+0.42%
1M Prestazione:
+4.00%
6M Prestazione:
-29.59%
1 anno Prestazione:
-45.63%
Intervallo 1D:
$21.29
$22.27
Intervallo di 1 settimana:
$21.12
$23.19
Portata 52W:
$18.41
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
21.34 | 2.06B | 672.72M | -575.44M | -487.00M | -5.8361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Phar - marketscreener.com
RARE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Ultragenyx EVP Pinion sells $228k in shares By Investing.com - Investing.com Nigeria
Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial - Yahoo
DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit ... - Bluefield Daily Telegraph
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - Yahoo Finance Singapore
Ultragenyx reveals positive Phase III results for DTX301 AAV8 gene therapy - The Pharma Letter
Russell Investments Group Ltd. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports positive Phase 3 data for OTC gene therapy By Investing.com - Investing.com India
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Sahm
Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026 - Meyka
Ultragenyx reports positive Phase 3 data for OTC gene therapy - Investing.com South Africa
JP Morgan Lowers Price Target for Ultragenyx Pharmaceutical (RAR - GuruFocus
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ... - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Leerink Partners reiterates Ultragenyx stock rating on trial data - Investing.com Nigeria
Ultragenyx Pharmaceutical Inc Announces Positive 36-Week Data From Phase 3 Study Of DTX301 AAV8 Gene Therapy For The Treatment Of Ornithine Transcarbamylase Deficiency - marketscreener.com
BofA reiterates Ultragenyx stock rating on positive gene therapy data - Investing.com
Leerink Partners reiterates Ultragenyx stock rating on trial data By Investing.com - Investing.com India
Ultragenyx gene therapy posts Phase III win for urea cycle disorder - FirstWord Pharma
Ultragenyx posts late-stage trial win for gene therapy in urea cycle disorder - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx Announces Positive Phase 3 Results for DTX301 - TipRanks
Ultragenyx (RARE) Sees Positive Phase 3 Results for Gene Therapy - GuruFocus
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency - The Manila Times
Ultragenyx's gene therapy helps control ammonia levels in late-stage study - marketscreener.com
RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
Assessing Ultragenyx Pharmaceutical (RARE) Valuation After Class Action And Failed Setrusumab Phase III Trials - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
Growth Value: What are the future prospects of Ultragenyx Pharmaceutical IncTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION - Finviz
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 – Company AnnouncementFT.com - Financial Times
Sands Capital Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - Morningstar
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Setrusumab Trial Setbacks and Securities Suits May Impact Ultragenyx Pharmaceutical (RARE) Investors - Sahm
Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - lincolnjournal.com
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):